Targeting NAMPT

The tumor microenvironment (TME) is no longer viewed as a passive backdrop to oncogenesis but as a dynamic orchestrator of therapeutic failure. At the 2026 American Association for Cancer Research (AACR) Annual Meeting, Hiba Siddiqui, BSc, shared insights into a specific signaling pathway that governs this resistance in bladder and prostate cancers: the CD44-SPP1 axis.

Translocation renal cell carcinoma (tRCC) represents a formidable clinical challenge, defined by its rarity and the absence of a consensus standard of care. Driven by specific gene fusions, this aggressive kidney cancer subtype often necessitates the exploration of novel molecular targets to improve patient outcomes. At the 2026 American Association for Cancer Research (AACR) Annual Meeting, Shikha Gupta, PhD, shared compelling data that could redefine the therapeutic approach for this population.

Background CDK4/6 inhibitors combined with endocrine therapy represent the standard of care for hormone receptor (HR)–positive, HER2-negative metastatic breast cancer (mBC). Despite their widespread use, real-world data evaluating racial differences in treatment outcomes and health care utilization remain limited. This study examined survival, progression, and hospital utilization among Black and White patients receiving CDK4/6 inhibitors.